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The objective of the study was to evaluate the efﬁcacy and safety of EUR-1008 for
the treatment of malabsorption in CF patients with EPI.
Study design: This multicenter, double blind, crossover, placebo-controlled trial was
performed at 14 US sites. The main study efﬁcacy endpoint was the comparison of
the coefﬁcient of fat absorption (CFA) during treatment with EUR-1008 vs. placebo.
Secondary endpoints included comparison of the coefﬁcient of nitrogen absorption
(CNA), incidence of clinical symptoms of EPI, blood levels of cholesterol, triglyc-
erides and fat soluble vitamins. The safety endpoints included the assessment of
adverse events, clinical laboratory parameters, physical examination ﬁndings and
vital sign measurements.
Results: Thirty-four patients (17F, aged 7−23/17M, aged 7−24) were enrolled with
31 patients completing all the phases of the study. Three patients discontinued
but none for treatment-related reasons. No drug-related serious adverse events
were reported. The CFA and CNA signiﬁcantly increased (p< 0.001) following
treatment with EUR-1008 vs placebo (88.28% vs 62.76% and 87.17% vs 65.67%,
respectively).
Cholesterol and vitamin K levels increased and symptoms of malabsorption were
controlled after treatment with EUR-1008.
Conclusion: In a randomized, double blind, placebo-controlled study, EUR-1008
was shown to be effective, safe and well tolerated for the treatment of EPI in CF
patients.
